A world-first clinical trial is launching to test an experimental vaccine designed to prevent lung cancer in people at high risk of the disease. 

Lung cancer remains the leading cause of cancer death in the UK, accounting for 20% of cancer deaths each year. 

Researchers from the University of Oxford and University College London have developed a preventative vaccine called LungVax, which has the potential to cut people’s lung cancer risk. Lab tests have shown it can prime the immune system to recognise and kill abnormal lung cells before they become cancerous. 

Sarah Blagden, Professor of Experimental Oncology at the University of Oxford and co-founder of the LungVax project, said: “Lung cancer is lethal and blights far too many lives. Survival has been stubbornly poor for decades. LungVax is our chance to do something to actively prevent this disease.” 

Cancer Research UK has awarded the LungVax team up to £2.06 ($2.7) million, supported by the CRIS Cancer Foundation, to begin testing the vaccine in a four-year Phase I trial, which is expected to begin in summer 2026. 

LungVax uses similar technology to the Oxford/AstraZeneca Covid-19 vaccine. 

Professor Mariam Jamal-Hanjani of University College London, who will lead the trial, said: “Fewer than 10% of people with lung cancer survive their disease for 10 years or more. That must change, and that change will come from targeting lung cancer at the earliest stages. The LungVax clinical trial is the crucial first step in bringing this vaccine to people at the highest risk of the disease. We will be looking carefully at how people respond to the vaccine, how easy it is to deliver, and who might benefit from it most in the future.”

Diana Turner, Deputy Editor, DDW